Scientific Resources
Our next-generation diagnostic assays have generated novel insights across a broad range of clinical applications.
Access our presentations, publications, and more to see how we’re unlocking the full potential of precision genomics.
Found 65 Results
June 3, 2025 | Poster
ALPHA3: A Pivotal Phase 2 Study of First‑Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients (Pts) With Large B‑Cell Lymphoma (LBCL) and Minimal Residual Disease (MRD) After Response to Standard Therapy
ASCO
June 3, 2025 | Poster
Sequencing-guided cHemotherapy Optimization Using Real-Time Evaluation in NewlyDiagnosed DLBCL With Circulating Tumor DNA: SHORTEN-ctDNA (NCT06693830)
ASCO
May 30, 2025 | Presentation
Prospective Validation of End-of-Treatment ctDNA-MRD by PhasED-Seq in 1L DLBCL Patients from a National Cohort
ASCO
February 6, 2025 | Abstract
Circulating Tumor DNA as Measurable Residual Disease in Aggressive B-Cell Lymphoma
JAMA Oncology
December 18, 2024 | Presentation
Clinical Trial Showcase at ASH 2024 – ALPHA3
ASH
December 17, 2024 | Presentation
Escalating Doses of AZD0486, a Novel CD19xCD3 T-cell Engager, Result in High Complete Remissions with Rapid Clearance of Minimal Residual Disease in Patients with Relapsed/Refractory Follicular Lymphoma
ASH